BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Novo Nordisk Gains on Wegovy Heart Benefits While Eli Lilly Slips
Novo Nordisk Gains on Wegovy Heart Benefits While Eli Lilly Slips
10
3
BTCCSquare news:
Novo Nordisk shares ROSE 1.6% in pre-market trading after revealing its Wegovy weight-loss drug demonstrated a 57% reduction in cardiovascular risks—outpacing rival Eli Lilly's therapies. The Danish firm's real-world study of 21,000 patients showed superior efficacy to Lilly's clinical trial data, sending LLY shares down 1.7%.
The divergence underscores the competitive stakes in the GLP-1 drug market, where Novo's semaglutide appears to offer unique cardioprotective effects. Investors are repricing expectations as real-world evidence carries greater weight than controlled studies.
By:
